AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies

Jennifer A. McCombe; Cecilia Zivelonghi; Nisa Vorasoot; Masoud Majed; Eoin P. Flanagan; Divyanshu Dubey; Sean J. Pittock; Andrew McKeon; Anastasia Zekeridou

doi:10.1016/j.jneuroim.2022.578012

AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies

Jennifer A. McCombe, Cecilia Zivelonghi, Nisa Vorasoot, Masoud Majed, Eoin P. Flanagan, Divyanshu Dubey, Sean J. Pittock, Andrew McKeon, Anastasia Zekeridou

Research output: Contribution to journal › Article › peer-review

Abstract

α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laboratory. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response. Thirty-one patients had at least one co-existing antibody that predicted thymoma in paraneoplastic patients (p = 0.008). In conclusion, in AMPAR encephalitis co-existing antibodies predict clinical presentation other than encephalitis and thymoma.

Original language	English (US)
Article number	578012
Journal	Journal of neuroimmunology
Volume	375
DOIs	https://doi.org/10.1016/j.jneuroim.2022.578012
State	Published - Feb 15 2023

Keywords

Encephalitis
Paraneoplastic neurological syndrome
Small cell lung cancer
Thymoma

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2022.578012

Cite this

@article{87072d13e68748449c90fa3ba57234ab,

title = "AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies",

abstract = "α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laboratory. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response. Thirty-one patients had at least one co-existing antibody that predicted thymoma in paraneoplastic patients (p = 0.008). In conclusion, in AMPAR encephalitis co-existing antibodies predict clinical presentation other than encephalitis and thymoma.",

keywords = "Encephalitis, Paraneoplastic neurological syndrome, Small cell lung cancer, Thymoma",

author = "McCombe, {Jennifer A.} and Cecilia Zivelonghi and Nisa Vorasoot and Masoud Majed and Flanagan, {Eoin P.} and Divyanshu Dubey and Pittock, {Sean J.} and Andrew McKeon and Anastasia Zekeridou",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2023",

month = feb,

day = "15",

doi = "10.1016/j.jneuroim.2022.578012",

language = "English (US)",

volume = "375",

journal = "Advances in Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - AMPAR autoimmunity

T2 - Neurological and oncological accompaniments and co-existing neural autoantibodies

AU - McCombe, Jennifer A.

AU - Zivelonghi, Cecilia

AU - Vorasoot, Nisa

AU - Majed, Masoud

AU - Flanagan, Eoin P.

AU - Dubey, Divyanshu

AU - Pittock, Sean J.

AU - McKeon, Andrew

AU - Zekeridou, Anastasia

PY - 2023/2/15

Y1 - 2023/2/15

N2 - α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laboratory. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response. Thirty-one patients had at least one co-existing antibody that predicted thymoma in paraneoplastic patients (p = 0.008). In conclusion, in AMPAR encephalitis co-existing antibodies predict clinical presentation other than encephalitis and thymoma.

AB - α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laboratory. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response. Thirty-one patients had at least one co-existing antibody that predicted thymoma in paraneoplastic patients (p = 0.008). In conclusion, in AMPAR encephalitis co-existing antibodies predict clinical presentation other than encephalitis and thymoma.

KW - Encephalitis

KW - Paraneoplastic neurological syndrome

KW - Small cell lung cancer

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=85145686223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145686223&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2022.578012

DO - 10.1016/j.jneuroim.2022.578012

M3 - Article

C2 - 36608398

AN - SCOPUS:85145686223

SN - 0165-5728

VL - 375

JO - Advances in Neuroimmunology

JF - Advances in Neuroimmunology

M1 - 578012

ER -

AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this